02 Hikma Pharmaceuticals PLC Group at a glance Diversified business Revenue by business segment Revenue by region 2005 2004 2005 2004 1.
Europe 18.8% 13.6% 7.8% 5.9% 3 3 3 3 1 1 1 1 2 2 2 2005 2 2004 Broad product portfolio Hikma sells 115 generic pharmaceutical products in 256 dosage strengths and forms in 34 countries.
Hikma also sells 25 pharmaceutical products under promotion and distribution agreements with, or licences from, 12 originator pharmaceutical companies and one generic pharmaceutical company.
The majority of Hikmas operations are in the United States, the Middle East and North Africa MENA and Europe.
Generic 2005 revenue Products 36 non-branded solid $115.2 million generic products Branded 2005 revenue Products $93.0 million 48 branded generic products 17 products under licence and or promotion and distribution agreements Injectable 2005 revenue Products $49.3 million 31 branded and non-branded injectable products 8 products under licence and or promotion and distribution agreements Hikma Pharmaceuticals PLC 03 Broad geographic coverage Our markets R&D centres Manufacturing plants including JPI, 47.5% owned associate Key markets Top products US ABC codeine Chloroquine phosphate Folic acid Lisinopril Lithium carbonate SR Key markets Top products Algeria, Jordan, Amoclan Saudi Arabia Oprazole Penamox Prograf Suprax Key markets Top products MENA, US, Europe Cefazolin sodium Ceftizoxime sodium Ceftriaxone sodium Cefuroxime sodium Ciprofloxacin
